Host T lymphocyte (T cell)

Host T cells, or T lymphocytes, are a primary lineage of the adaptive immune system responsible for cell-mediated immunity. They are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface, which allows them to recognize specific antigens presented by major histocompatibility complex (MHC) molecules [1][2]. These cells play diverse roles, including the direct killing of infected or cancerous cells (CD8+ cytotoxic T cells) and the coordination of the broader immune response through cytokine secretion (CD4+ helper T cells) [2][3]. In clinical medicine, host T cells are frequently the focus of therapeutic strategies; for instance, they are suppressed to prevent organ transplant rejection and graft-versus-host disease, or they are activated and unleashed via checkpoint inhibitors to treat various malignancies [4][5]. Because they are central to both defense and pathology, pharmacological manipulation of host T cells requires a careful balance to avoid systemic immunosuppression or hyper-inflammatory states like cytokine release syndrome [5][6]. Consequently, they represent a broad cellular target rather than a single molecular entity, with various drugs acting on specific receptors or signaling pathways within the cell [1][4].

Other names

T lymphocytesThymus-derived cellsHost T-cellsT-cells

Drugs targeting host T cells act through several mechanisms: calcineurin inhibitors (e.g., cyclosporine) block T-cell activation by inhibiting IL-2 production; checkpoint inhibitors (e.g., pembrolizumab) block inhibitory signals like PD-1 to enhance anti-tumor activity; and monoclonal antibodies (e.g., muromonab-CD3) can deplete or modulate T-cell populations directly [4][5][6].